Diagnostic usefulness of HBME1, galectin-3, CK19, and CITED1 and evaluation of their expression in encapsulated lesions with questionable features of papillary thyroid carcinoma

American Journal of Clinical Pathology

Volumn 126, Issue 5, 2006, Pages 700-708

  Scognamiglio, Theresa ^a,b   Hyjek, Elizabeth ^a   Kao, Jean ^a   Chen, Yao Tseng ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b Dept of Pathology ^*  (United States)

Author keywords

CITED1; Cytokeratin 19; Follicular adenoma; Galectin 3; HBME1; Immunohistochemistry; Papillary carcinoma; Thyroid

Indexed keywords

BIOLOGICAL MARKER; CYTOKERATIN 19; GALECTIN 3; GENE PRODUCT; PROTEIN CITED1; PROTEIN HBME1; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL FEATURE; DIAGNOSTIC PROCEDURE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY; STAINING; THYROID ADENOMA; THYROID FOLLICULAR ADENOMA; THYROID PAPILLARY CARCINOMA; TISSUE MICROARRAY;

EID: 33750736320     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/044V86JN2W3CN5YB     Document Type: Article

References (48)

1. Renshaw AA, Gould EW. Why there is the tendency to " overdiagnose" the follicular variant of papillary thyroid carcinoma. Am J Clin Pathol. 2002;117:19-21.
2. Chan JK. Strict criteria should be applied in the diagnosis of encapsulated follicular variant of papillary thyroid carcinoma. Am J Clin Pathol. 2002;117:1648.
3. Saxen E, Franssila K, Bjarnason O, et al. Observer variation in histologic classification of thyroid cancer. Acta Pathol Microbiol Scand[A]. 1978;86A:483-486.
4. Hirokawa M, Carney JA, Goellner JR, et al. Observer variation of encapsulated follicular lesions of the thyroid gland. Am J Surg Pathol. 2002;26:1508-1514.
5. Franc B. Observer variation of lesions of the thyroid. Am J Surg Pathol. 2003;27:1177-1179.
6. Lloyd RV, Erickson LA, Casey MB, et al. Observer variation in the diagnosis of follicular variant of papillary thyroid carcinoma. Am J Surg Pathol. 2004;28:1336-1340.
7. Williams ED. Two proposals regarding the terminology of thyroid tumors [editorial]. Int J Surg Pathol. 2000;8:181-183.
8. Papotti M, Rodriguez J, De Pompa R, et al. Galectin-3 and HBME-1 expression in well-differentiated thyroid tumors with follicular architecture of uncertain malignant potential. Mod Pathol. 2005;18:541-546.
9. Vasko VV, Gaudart J, Allasia C, et al. Thyroid follicular adenomas may display features of follicular carcinoma and follicular variant of papillary carcinoma. Eur J Endocrinol. 2004;151:779-786.
10. Fusco A, Chiappetta G, Hui P, et al. Assessment of RET/PTC oncogene activation and clonality in thyroid nodules with incomplete morphological evidence of papillary carcinoma: a search for the early precursors of papillary cancer. Am J Pathol. 2002;160:2157-2167.
11. Sheibani K, Esteban JM, Bailey A, et al. Immunopathologic and molecular studies as an aid to the diagnosis of malignant mesothelioma. Hum Pathol. 1992;23:107-116.
12. Miettinen M, Karkkainen P. Differential reactivity of HBME-1 and CD15 antibodies in benign and malignant thyroid tumours: preferential reactivity with malignant tumours. Virchows Arch. 1996;429:213-219.
13. Sack MJ, Astengo-Osuna C, Lin BT, et al. HBME-1 immunostaining in thyroid fine-needle aspirations: a useful marker in the diagnosis of carcinoma. Mod Pathol. 1997;10:668-674.
14. Cheung CC, Ezzat S, Freeman JL, et al. Immunohistochemical diagnosis of papillary thyroid carcinoma. Mod Pathol. 2001;14:338-342.
15. Choi YL, Kim MK, Suh JW, et al. Immunoexpression of HBME-1, high molecular weight cytokeratin, cytokeratin 19, thyroid transcription factor-1, and E-cadherin in thyroid carcinomas. J Korean Med Sci. 2005;20:853-859.
16. de Matos PS, Ferreira AP, de Oliveira Facuri F, et al. Usefulness of HBME-1, cytokeratin 19 and galectin-3 immunostaining in the diagnosis of thyroid malignancy. Histopathology. 2005;47:391-401.
17. Ito Y, Yoshida H, Tomoda C, et al. HBME-1 expression in follicular tumor of the thyroid: an investigation of whether it can be used as a marker to diagnose follicular carcinoma. Anticancer Res. 2005;25:179-182.
18. Rossi ED, Raffaelli M, Minimo C, et al. Immunocytochemical evaluation of thyroid neoplasms on thin-layer smears from fine-needle aspiration biopsies. Cancer. 2005;105:87-95.
19. Prasad ML, Pellegata NS, Huang Y, et al. Galectin-3, fibronectin-1, CITED-1, HBME1 and cytokeratin-19 immunohistochemistry is useful for the differential diagnosis of thyroid tumors. Mod Pathol. 2005;18:48-57.
20. Raphael SJ, McKeown-Eyssen G, Asa SL. High-molecular-weight cytokeratin and cytokeratin-19 in the diagnosis of thyroid tumors. Mod Pathol. 1994;7:295-300.
21. Baloch ZW, Abraham S, Roberts S, et al. Differential expression of cytokeratins in follicular variant of papillary carcinoma: an immunohistochemical study and its diagnostic utility. Hum Pathol. 1999;30:1166-1171.
22. Sahoo S, Hoda SA, Rosai J, et al. Cytokeratin 19 immunoreactivity in the diagnosis of papillary thyroid carcinoma: a note of caution. Am J Clin Pathol. 2001;116:696-702.
23. Cameron BR, Berean KW. Cytokeratin subtypes in thyroid tumours: immunohistochemical study with emphasis on the follicular variant of papillary carcinoma. J Otolaryngol. 2003;32:319-322.
24. Hirokawa M, Inagaki A, Kobayashi H, et al. Expression of cytokeratin 19 in cytologic specimens of thyroid [letter]. Diagn Cytopathol. 2000;22:197-198.
25. Beesley MF, McLaren KM. Cytokeratin 19 and galectin-3 immunohistochemistry in the differential diagnosis of solitary thyroid nodules. Histopathology. 2002;41:236-243.
26. Erkilic S, Aydin A, Kocer NE. Diagnostic utility of cytokeratin 19 expression in multinodular goiter with papillary areas and papillary carcinoma of thyroid. Endocr Pathol. 2002;13:207-211.
27. Casey MB, Lohse CM, Lloyd RV. Distinction between papillary thyroid hyperplasia and papillary thyroid carcinoma by immunohistochemical staining for cytokeratin 19, galectin-3, and HBME-1. Endocr Pathol. 2003;14:55-60.
28. Erkilic S, Kocer NE. The role of cytokeratin 19 in the differential diagnosis of true papillary carcinoma of thyroid and papillary carcinoma-like changes in Graves' disease. Endocr Pathol. 2005;16:63-66.
29. Xu XC, el-Naggar AK, Lotan R. Differential expression of galectin-1 and galectin-3 in thyroid tumors: potential diagnostic implications. Am J Pathol. 1995;147:815-822.
30. Orlandi F, Saggiorato E, Pivano G, et al. Galectin-3 is a presurgical marker of human thyroid carcinoma. Cancer Res. 1998;58:3015-3020.
31. Oestreicher-Kedem Y, Halpern M, Roizman P, et al. Diagnostic value of galectin-3 as a marker for malignancy in follicular patterned thyroid lesions. Head Neck. 2004;26:960-966.
32. Saggiorato E, Aversa S, Deandreis D, et al. Galectin-3: presurgical marker of thyroid follicular epithelial cell-derived carcinomas. J Endocrinol Invest. 2004;27:311-317.
33. Huang Y, Prasad M, Lemon WJ, et al. Gene expression in papillary thyroid carcinoma reveals highly consistent profiles. Proc Natl Acad Sci USA. 2001;98:15044-15049.
34. Finley DJ, Arora N, Zhu B, et al. Molecular profiling distinguishes papillary carcinoma from benign thyroid nodules. J Clin Endocrinol Metab. 2004;89:3214-3223.
35. Prasad ML, Pellegata NS, Kloos RT, et al. CITED1 protein expression suggests papillary thyroid carcinoma in high throughput tissue microarray-based study. Thyroid. 2004;14:169475.
36. Scognamiglio T, Hyjek E, Chen Y. Papillary thyroid carcinoma versus follicular adenoma: analysis of keratin 19, galectin-3, and CITED1 expression by tissue microarray [abstract]. Mod Pathol. 2005;18(suppl 1):218A.
37. Chen YT, Stockert E, Chen Y, et al. Identification of the MAGE-1 gene product by monoclonal and polyclonal antibodies. Proc Natl Acad Sci USA. 1994;91:1004-1008.
38. Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med. 1998;4:844-847.
39. Hoos A, Stojadinovic A, Singh B, et al. Clinical significance of molecular expression profiles of Hürthle cell tumors of the thyroid gland analyzed via tissue microarrays. Am J Pathol. 2002;160:175-183.
40. Hoos A, Urist MJ, Stojadinovic A, et al. Validation of tissue microarrays for immunohistochemical profiling of cancer specimens using the example of human fibroblastic tumors. Am J Pathol. 2001;158:1245-1251.
41. Saggiorato E, De Pompa R, Volante M, et al. Characterization of thyroid "follicular neoplasms" in fine-needle aspiration cytological specimens using a panel of immunohistochemical markers: a proposal for clinical application. Endocr Relat Cancer. 2005;12:305-317.
42. Nasr M, Mukhopadhyay S, Zhang S, et al. Reevaluation of immunohistochemical markers in diagnosing papillary carcinoma (PC) of the thyroid: evidence for utility of HBME1 combined with CK19 immunostaining [abstract]. Mod Pathol. 2006;86(suppl 1):95A.
43. Fernandez PL, Merino MJ, Gomez M, et al. Galectin-3 and laminin expression in neoplastic and non-neoplastic thyroid tissue. J Pathol. 1997;181:80-86.
44. Inohara H, Honjo Y, Yoshii T, et al. Expression of galectin-3 in fine-needle aspirates as a diagnostic marker differentiating benign from malignant thyroid neoplasms. Cancer. 1999;85:2475-2484.
45. Mehrotra P, Okpokam A, Bouhaidar R, et al. Galectin-3 does not reliably distinguish benign from malignant thyroid neoplasms. Histopathology. 2004;45:493-500.
46. Bartolazzi A, Bussolati G. Galectin-3 does not reliably distinguish benign from malignant thyroid neoplasms [letter]. Histopathology. 2006;48:212-213.
47. Martins L, Matsuo SE, Ebina KN, et al. Galectin-3 messenger ribonucleic acid and protein are expressed in benign thyroid tumors. J Clin Endocrinol Metab. 2002;87:4806-4810.
48. Adeniran AJ, Zhu Z, Gandhi M, et al. Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas. Am J Surg Pathol. 2006;30:216-222.